艾伯维“狙击”普方生物:专利战下 政策如何助力行业规范?

21世纪经济报道
25 Mar

继起诉百济神州(BeiGene)之后,艾伯维(AbbVie)将矛头指向普方生物 。日前,国外一家生物技术公司Genmab发布公告称,艾伯维向美国华盛顿西区地方法院提起诉讼,将Genmab、普方生物美国分部、普方生物苏州研发中心、艾伯维前员工列为被告,指控被告方旗下ADC药物Rina-S,未经授权使用了一项旨在增强ADC亲水性的基于二糖的连接技术,涉及其商业秘密。Genmab方面坚决否认上述指控,“...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10